Heinrich Worth1, Roland Buhl2, Carl-Peter Criée3, Peter Kardos4, Claudia Mailänder5, Claus Vogelmeier6. 1. Facharztforum Fürth, 90762, Fürth, Germany. Electronic address: heinrich.worth@t-online.de. 2. Pulmonary Department, Mainz University Hospital, 55131, Mainz, Germany. 3. Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, 37120, Bovenden, Germany. 4. Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, 60318, Frankfurt am Main, Germany. 5. Clinical Research Primary Care, Novartis Pharma GmbH, D-90429, Nuernberg, Germany. 6. Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL) 35043, Marburg, Germany.
Abstract
INTRODUCTION: DACCORD is an ongoing, longitudinal, non-interventional study within the German COPD National Prospective Registry. This manuscript describes the baseline characteristics of the first 5924 participants, recruited between November 2012 and November 2013. METHODS: The main inclusion criteria are a physician diagnosis of COPD, age ≥40 years, and initiating or changing COPD maintenance medication. Data collected included: Demographic and disease characteristics; prescribed medication; symptoms; COPD Assessment Test (CAT); modified Medical Research Council dyspnoea score (mMRC); exacerbations; comorbidities; and forced expiratory volume in 1 s (FEV1). RESULTS: Approximately 60% of the population are male, with mean age of 65.7 years and FEV1 61.6% predicted. On entry to the study the majority of patients reported symptoms, most commonly exertional dyspnoea (85.9%) and cough (65.7%). According to GOLD 2010, 48.6% of patients were classified as GOLD II. GOLD 2011 classification was influenced by the symptoms criterion: 43.7 and 45.3% of patients were classified as GOLD B or D using CAT, compared with 26.4 and 34.0%, respectively, using mMRC. The majority of patients were receiving a LAMA-containing regimen, with 39.4% overall receiving ICS. A total of 78.3% of patients reported at least one comorbidity, most commonly cardiovascular. CONCLUSION: In conclusion, DACCORD is a large, prospective, non-interventional study that provides an informative and intriguing picture of the typical COPD patient in Germany.
INTRODUCTION: DACCORD is an ongoing, longitudinal, non-interventional study within the German COPD National Prospective Registry. This manuscript describes the baseline characteristics of the first 5924 participants, recruited between November 2012 and November 2013. METHODS: The main inclusion criteria are a physician diagnosis of COPD, age ≥40 years, and initiating or changing COPD maintenance medication. Data collected included: Demographic and disease characteristics; prescribed medication; symptoms; COPD Assessment Test (CAT); modified Medical Research Council dyspnoea score (mMRC); exacerbations; comorbidities; and forced expiratory volume in 1 s (FEV1). RESULTS: Approximately 60% of the population are male, with mean age of 65.7 years and FEV1 61.6% predicted. On entry to the study the majority of patients reported symptoms, most commonly exertional dyspnoea (85.9%) and cough (65.7%). According to GOLD 2010, 48.6% of patients were classified as GOLD II. GOLD 2011 classification was influenced by the symptoms criterion: 43.7 and 45.3% of patients were classified as GOLD B or D using CAT, compared with 26.4 and 34.0%, respectively, using mMRC. The majority of patients were receiving a LAMA-containing regimen, with 39.4% overall receiving ICS. A total of 78.3% of patients reported at least one comorbidity, most commonly cardiovascular. CONCLUSION: In conclusion, DACCORD is a large, prospective, non-interventional study that provides an informative and intriguing picture of the typical COPDpatient in Germany.
Authors: Peter Kardos; Sally Worsley; Dave Singh; Miguel Román-Rodríguez; David E Newby; Hana Müllerová Journal: Int J Chron Obstruct Pulmon Dis Date: 2016-11-25
Authors: Claus Vogelmeier; Heinrich Worth; Roland Buhl; Carl-Peter Criée; Nadine S Lossi; Claudia Mailänder; Peter Kardos Journal: Int J Chron Obstruct Pulmon Dis Date: 2017-02-01
Authors: Peter Kardos; Claus F Vogelmeier; Heinrich Worth; Roland Buhl; Victoria Obermoser; Carl-Peter Criée Journal: Lung Date: 2020-05-04 Impact factor: 2.584
Authors: Roland Buhl; Carl-Peter Criée; Peter Kardos; Claus F Vogelmeier; Konstantinos Kostikas; Nadine S Lossi; Heinrich Worth Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-08-24
Authors: Eleonore H Koolen; Philip J van der Wees; Gert P Westert; Richard Dekhuijzen; Yvonne F Heijdra; Alex J van 't Hul Journal: Int J Chron Obstruct Pulmon Dis Date: 2018-07-19
Authors: Timm Greulich; Jens M Hohlfeld; Petra Neuser; Katrin Lueer; Andreas Klemmer; Carmen Schade-Brittinger; Susanne Harnisch; Holger Garn; Harald Renz; Ursula Homburg; Jonas Renz; Anne Kirsten; Frauke Pedersen; Meike Müller; Claus F Vogelmeier; Henrik Watz Journal: Respir Res Date: 2018-04-04